Category Archives: HIV care & treatment

New combo pill of Prezista + cobicistat gets submitted to FDA


According to an April 1, 2014 press release from Janssen Research & Development, a new drug application has been submitted to the FDA for a new combination pill made up of the protease inhibitor Prezista (darunavir) and the boosting drug called cobicistat. Cobicistat is currently co-formulated…Read More

Rare case of HIV transmission occurs between two lesbians


In the March 14, 2014 edition of the CDC’s Morbidity and Mortality Weekly Report, a rare case of female-to-female transmission of HIV appears to have occurred between two lesbians in a monogamous mixed-status relationship. The article states a 46-year-old HIV-negative woman appears to have gotten HIV…Read More

President Obama Announces Douglas M. Brooks, MSW, as Director of the Office of National AIDS Policy


Reprinted from a White House press release WASHINGTON, DC – Today, President Obama announced the appointment of Douglas M. Brooks, MSW, as the Director of the White House Office of National AIDS Policy (ONAP). A leading HIV/AIDS policy expert, Douglas most recently served as Senior Vice…Read More

Is HIV becoming more virulent over time? Study says yes.


The standard wisdom says that people generally have ten years of decent health following HIV transmission before they get sick or die. But what if that information is now incorrect? That is the question that researchers from the CASCADE HIV cohort study tried to answer, when…Read More

Learning from failure: virus rebound in transplant patients likely came from tiny pool of infected cells


As reported in December the two “Boston patients,” whom researchers had hoped were in HIV remission ultimately had a return of HIV several months after stopping antiretroviral (ARV) therapy. Now the scientists are hard at work trying to figure out why, and the culprit seems to…Read More

Isentress edges out Prezista and Reyataz in comparison study of people new to HIV treatment


At the 2014 CROI (Conference on Retroviruses and Opportunistic Infections) in Boston, results from the ACTG A5257 study compared three different HIV regimens on how well they controlled HIV and how well patients tolerated them. All of the regimens are “preferred” options in the federal HIV…Read More

Adding vitamin D and calcium to a new HIV regimen curbs bone loss in the hip


In a presentation at the 2014 CROI (Conference on Retroviruses and Opportunistic Infections) in Boston, taking high-dose vitamin D and calcium every day reduced the loss of hip bone mass in people who started on a regimen of efavirenz (Sustiva) + tenofovir/emtricitabine (Truvada). Studies have shown…Read More